NRI Secure Launches Japan's First "Blockchain Assessment" Service
21.7.2017 10:00 | Business Wire
NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/
Overview of the "Blockchain Assessment" Service (Graphic: Business Wire)
As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or even to actual damage*4 by causing services to behave differently than originally intended.
In response to these issues, NRI Secure has systematized its accumulated knowledge and insights in the form of the “Blockchain Assessment” service. As its first step, NRI Secure will be launching the security assessment service for smart contracts. The service performs assessment from the dual perspectives of static analysis, which carefully analyzes a program, and dynamic analysis, which involves simulating a real attack, in order to identify vulnerabilities.
More assessment menus for other constituent elements of the blockchain will be added in the future. (2 to 4 in the overview diagram). This service is only available in English and Japanese.
NRI Secure continues to provide a variety of products and services for supporting companies and organizations in their information security measures, and to contribute to the creation of a safe information system environment and society on a global scale.
|*1||First-ever in Japan: This is the first security assessment service designed specifically for the blockchain to be provided by a medium- or large-scale security vendor in Japan (according to NRI Secure research).|
|*2||Blockchain technology: A technology which achieves a distributed consensus among its participants and makes it possible to manage audit trails for all transactions, without the intervention of a trusted third party. Given such features as its ability to make falsifying data extremely difficult, its near-zero downtime, its lack of a centralized manager, and its high transaction performance, the blockchain has been lauded for being inexpensive to develop and for its potentially broad application as a way for companies to exchange information. These features have led to expectations that the blockchain can be used not only for cryptocurrencies such as Bitcoin, but as a circulation platform for transactions involving various asset types. Furthermore, this technology is also gaining notice for its potential use in the recording and storage of more common types of contracts, as well as in automatic contract execution.|
|*3||Smart contracts: This refers to contracts which are programmed and can be automatically executed. A smart contract is arranged with the execution conditions and contractual terms prescribed in advance, such that the contract is automatically executed when a transaction occurs matching said conditions. Smart contracts are being considered for use in securities settlements, real property transactions, the sharing economy, and numerous other fields that involve contracts.|
|*4||Actual damage: “The DAO Incident” occurred on June 17, 2016. Funds (virtual currency) held by “The DAO,” a virtual corporation established by a Germany-based venture capital company, were transmitted to a cyber-attacker who had exploited vulnerabilities in The DAO’s smart contract programming code.|
|*5||DApps: This abbreviation stands for Decentralized Applications, and refers to applications that are decentralized and distributed. They are said to enable the use of highly-reliably, low-cost applications via blockchain technology, without the need for a centralized system manager.|
About NRI Secure
NRI SecureTechnologies is a subsidiary of Nomura Research Institute
(NRI) specializing in Cybersecurity, and a leading global provider of
next-generation managed security services and security consulting.
Established in 2000, NRI SecureTechnologies is focused on delivering
high-value security outcomes for our clients with the precision and
efficiency that define Japanese quality.
For more details, visit us at http://www.nri-secure.com
“Blockchain Assessment” Service
Supported platforms: Ethereum, Hyperledger Fabric
*Additional platforms will be supported at a later time.
Supported languages: Solidity, Go, Java
*Please contact us regarding any other languages.
- Price: Estimates will be provided on an individual basis.
- For more details on the “Blockchain Assessment” Service, please contact: email@example.com.
NRI SecureTechnologies, Ltd.
Hitomi Nemoto, +81-3-6706-0622
NRI SecureTechnologies, Ltd.
Teruhiro Tagomori / Takenori Kiuchi, +81-3-6706-0622
Cyber Security Services Department II
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 16:25 | Tiedote
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the
IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 15:00 | Tiedote
IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman
PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 11:03 | Tiedote
PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate
Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 11:00 | Tiedote
Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The
Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 10:08 | Tiedote
Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven
Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 09:00 | Tiedote
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme